The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.
… Conference call top-line results Phase 2/3 Illuminate trial Webcast information Company management will host a call … discuss the top-line results of the Phase 2/3 Illuminate clinicaltrial of investigational RNA therapy sepofarsen in …
… Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 In … French and German . Illuminate Illuminate is the name of a clinical study which aimed to explore whether the … an injection with no medicine or injection given. Clinical trials are used by researchers to find out whether …
… Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinicaltrial of QR-010 in CF patients with the F508del …
